Keros Therapeutics (NASDAQ:KROS) Announces Quarterly Earnings Results

Keros Therapeutics (NASDAQ:KROS) posted its quarterly earnings results on Wednesday. The company reported ($1.14) EPS for the quarter, topping analysts’ consensus estimates of ($1.36) by $0.22, Zacks reports. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The firm had revenue of $3.04 million during the quarter, compared to analyst estimates of $37.32 million.

Keros Therapeutics Trading Down 0.7 %

Keros Therapeutics stock traded down $0.08 during mid-day trading on Friday, hitting $10.93. The company’s stock had a trading volume of 148,478 shares, compared to its average volume of 1,573,935. The firm has a market capitalization of $442.66 million, a PE ratio of -2.11 and a beta of 1.39. Keros Therapeutics has a 1 year low of $9.77 and a 1 year high of $73.00. The stock’s fifty day moving average is $12.64 and its two-hundred day moving average is $39.79.

Analyst Upgrades and Downgrades

KROS has been the subject of several research analyst reports. TD Cowen lowered Keros Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Jefferies Financial Group started coverage on Keros Therapeutics in a report on Tuesday, November 5th. They issued a “buy” rating on the stock. Cantor Fitzgerald cut Keros Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Tuesday, January 21st. Wells Fargo & Company cut their price objective on Keros Therapeutics from $28.00 to $26.00 and set an “overweight” rating on the stock in a research report on Thursday. Finally, Oppenheimer cut their price objective on Keros Therapeutics from $63.00 to $23.00 and set an “outperform” rating on the stock in a research report on Thursday, January 16th. Six analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $42.33.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.